Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian D Lehmann

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Nature Communications|November 2, 2021
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesBrian D Lehmann, Antonio Colaprico, Tiago C Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2025
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast CancerPaula I Gonzalez-Ericsson, Nisha Unni, Komal Jhaveri, et al.
American Journal of Respiratory and Critical Care Medicine|November 6, 2023
Loss of p73 Expression Contributes to Chronic Obstructive Pulmonary DiseaseBradley W Richmond, Clayton B Marshall, Jessica B Blackburn, et al.
NPJ Breast Cancer|March 12, 2025
Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancerPadma Sheila Rajagopal, Sonya Reid, Run Fan, et al.
Breast Cancer Research and Treatment|February 9, 2018
First international TNBC conference meeting reportPadmashree Rida, Angela Ogden, Ian O Ellis, et al.
JAMA Oncology|December 14, 2023
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical TrialBrian D Lehmann, Vandana G Abramson, E Claire Dees, et al.
Clinical and Translational Medicine|October 17, 2024
Single-cell transcriptional atlas of human breast cancers and model systemsJulia E Altman, Amy L Olex, Emily K Zboril, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2025
The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial CancerErica V Carballo, Paula Gonzalez-Ericsson, Brian D Lehmann, et al.
Molecular Oncology|August 7, 2013
SPARCL1 suppresses metastasis in prostate cancerYuzhu Xiang, Qingchao Qiu, Ming Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Nature Communications|November 2, 2021
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesBrian D Lehmann, Antonio Colaprico, Tiago C Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2025
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast CancerPaula I Gonzalez-Ericsson, Nisha Unni, Komal Jhaveri, et al.
American Journal of Respiratory and Critical Care Medicine|November 6, 2023
Loss of p73 Expression Contributes to Chronic Obstructive Pulmonary DiseaseBradley W Richmond, Clayton B Marshall, Jessica B Blackburn, et al.
NPJ Breast Cancer|March 12, 2025
Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancerPadma Sheila Rajagopal, Sonya Reid, Run Fan, et al.
Breast Cancer Research and Treatment|February 9, 2018
First international TNBC conference meeting reportPadmashree Rida, Angela Ogden, Ian O Ellis, et al.
JAMA Oncology|December 14, 2023
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical TrialBrian D Lehmann, Vandana G Abramson, E Claire Dees, et al.
Clinical and Translational Medicine|October 17, 2024
Single-cell transcriptional atlas of human breast cancers and model systemsJulia E Altman, Amy L Olex, Emily K Zboril, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2025
The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial CancerErica V Carballo, Paula Gonzalez-Ericsson, Brian D Lehmann, et al.
Molecular Oncology|August 7, 2013
SPARCL1 suppresses metastasis in prostate cancerYuzhu Xiang, Qingchao Qiu, Ming Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Pageof 7